- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00879905
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors
6 dicembre 2020 aggiornato da: Novartis Pharmaceuticals
A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally in Adult Patients With Advanced Solid Malignancies
This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week or twice weekly to subjects with advanced solid tumors.
Panoramica dello studio
Tipo di studio
Interventistico
Iscrizione (Effettivo)
64
Fase
- Fase 1
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Patients with histologically confirmed, advanced malignant solid tumors whose disease has progressed on standard therapy or for whom no standard therapy exists
- All patients must have at least one measurable lesion as defined by RECIST. Irradiated lesions are only evaluable for disease progression
- All patients must have documented progressive disease before entering the study
- Age ≥ 18 years
- World Health Organization (WHO) Performance Status ≤ 2
- Life expectancy of ≥ 12 weeks
- Patients must have the certain laboratory values
- Patients able and willing to swallow capsules
- Ability to understand the patient information and informed consent form and comply with the protocol
- Signed and dated written informed consent is available
- Only for patients enrolled at MTD: willing to provide a fresh pre-dose and post-dose tumor biopsy.
Exclusion Criteria:
- Patients with present or history of CNS metastasis.
- Prior treatment with any Hsp90 or HDAC inhibitor compound.
- Patients who have not recovered from side effects of previous systemic anticancer therapy to < CTCAE Grade 2 prior to the first dose
- Patients identified to be "poor or intermediate CYP2C9 metabolizers"
Patients who received systemic anti-cancer treatment prior to the first dose of HSP990 within the following time frames:
- Patients who have received cyclical chemotherapy within a period of time that is shorter than the cycle length used for that treatment (e.g., 6 weeks for nitrosourea, mitomycin-C) prior to starting study drug or who have not recovered from the side effects of such therapy
- Patients who have received biologic therapy (e.g., antibodies) within a period of time that is ≤ 4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy
- Patients who have been treated with a continuous or intermittent small molecule therapeutic within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks (whichever is shorter) prior to starting study drug or who have not recovered from the side effects of such therapy
- Patients who have received any other investigational agents within a period of time that is ≤ 5 t1/2 or less than the cycle length used for that treatment or ≤ 4 weeks (whichever is shorter) prior to starting study drug or who have not recovered from the side effects of such therapy
- Patients who have received wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
- Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
- Treatment with therapeutic doses of sodium warfarin (Coumadin).
- Patients using medications that are CYP2C9 inhibitors and/or medications known to have QT prolongation effect and cannot be switched or discontinued to an alternative drug prior to commencing HSP990 dosing.
- Unresolved diarrhea ≥ CTCAE grade 2
- Patients who do not have either an archival tumor sample available or readily obtainable in the course of the study or are unwilling to have a fresh tumor sample collected at baseline.
- Pregnant or lactating women.
- Fertile women of childbearing potential (WCBP) not using adequate contraception (abstinence, oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile). Male patients whose partners are WCBP, not using adequate contraception.
- Acute or chronic liver disease.
- Acute or chronic renal disease.
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of HSP990
- Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol.
- Known diagnosis of HIV infection (HIV testing is not mandatory).
- Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
Cardiac exclusion criteria:
- History (or family history) of long QT syndrome.
- Mean QTcF ≥ 480 msec on screening ECG
- History of clinically manifest ischemic heart disease including myocardial infarction, or unstable angina ≤ 3 months prior to study start.
- Left ventricular (LV) dysfunction (LVEF ≤ 45%) by MUGA or ECHO
- Clinically significant ECG abnormalities including one or more of the following: left bundle branch block (LBBB), right bundle branch block (RBBB) with left anterior hemiblock (LAHB), or 3rd degree AV block.
- History or presence of atrial fibrillation, atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de Pointes.
- Clinically significant resting bradycardia (< 50 beats per minute).
- Patients who are currently receiving treatment with any medication which has a relative risk or prolonging the QTcF interval or inducing Torsades de Pointes (as listed in Post-text supplement 2) and cannot be switched or discontinued to an alternative drug prior to commencing HSP990 dosing.
- Obligate use of a cardiac pacemaker.
- Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
Other protocol-defined inclusion/exclusion criteria may apply
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: once weekly dosing schedule
|
|
Sperimentale: twice weekly dosing schedule
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Maximum Tolerated Dose of HSP990 in patients treated once weekly or twice weekly
Lasso di tempo: At the end of the dose escalation phase of the study
|
At the end of the dose escalation phase of the study
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
True DLT rate
Lasso di tempo: At the end of the 1st 4 weeks of treatment
|
At the end of the 1st 4 weeks of treatment
|
Preliminary Efficacy
Lasso di tempo: Every 2 months (or 8 weeks, which equals 2 treatment cycles)
|
Every 2 months (or 8 weeks, which equals 2 treatment cycles)
|
Drug metabolism in Humans, PK, PD
Lasso di tempo: every 4 weeks
|
every 4 weeks
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 maggio 2009
Completamento primario (Effettivo)
1 luglio 2012
Completamento dello studio (Effettivo)
1 luglio 2012
Date di iscrizione allo studio
Primo inviato
9 aprile 2009
Primo inviato che soddisfa i criteri di controllo qualità
10 aprile 2009
Primo Inserito (Stima)
13 aprile 2009
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
8 dicembre 2020
Ultimo aggiornamento inviato che soddisfa i criteri QC
6 dicembre 2020
Ultimo verificato
1 ottobre 2012
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CHSP990A2101
- 2008-006440-19 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Neoplasie solide avanzate
-
Rush University Medical CenterCompletatoAdvanced Cardiac Life Support, rianimazione cardiopolmonare, volume corrente, ventilazione manualeStati Uniti
-
The Leeds Teaching Hospitals NHS TrustAttivo, non reclutanteFerite e lesioni | Chirurgia | Riabilitazione | Disturbo ortopedico | Misure di esito riferite dal paziente | Valutazione della disabilità | Recupero della funzione | Trauma multiplo/lesioni | Centri traumatologici | Indici di gravità del trauma | Advanced Trauma Life Support CareRegno Unito
-
Advanced BionicsCompletatoPerdita dell'udito da grave a profonda | negli utenti adulti di Advanced Bionics HiResolution™ Bionic Ear SystemStati Uniti
-
AstraZenecaReclutamentoAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, carcinoma gastrico, mammario e ovaricoSpagna, Stati Uniti, Belgio, Regno Unito, Francia, Ungheria, Canada, Corea, Repubblica di, Australia
Prove cliniche su HSP990
-
Novartis PharmaceuticalsTerminato